Kodiak's KSI-101 heads to Phase 3 readout after Phase 1b BCVA and drying data
PEAK trial data due by early 2027 must replicate the vision gains and rapid retinal drying KSI-101 showed in a 39-patient Phase 1b study, in a disease with no approved treatment.
Executive Summary
- Kodiak's pivotal trial in an inflammatory eye disease with no approved treatment is approaching a topline readout that will test whether a small, uncontrolled early-stage signal survives a randomized, sham-controlled Phase 3 design.
- Early data showed rapid vision gains and high rates of retinal fluid resolution after a single dose, giving the Phase 3 trial a specific, previously disclosed benchmark to reproduce rather than a vague efficacy hope.
- The sponsor has held its guided readout quarter steady across six disclosures even as the trial's own registry completion date pushed later and its enrollment target rose sharply, a divergence investors should track heading into the readout.
- No other program combines interleukin-6 and VEGF blockade in this indication, leaving the trial without a direct mechanistic precedent to benchmark against inside the same disease population.
The catalyst
Kodiak has told investors since September 2025 that topline data from the Phase 3 PEAK study (NCT06990399) and its companion PINNACLE trial (NCT06996080) would land in the fourth quarter of 2026 or the first quarter of 2027. That guidance has repeated unchanged across at least six subsequent disclosures through May 2026. PEAK is a registrational, randomized, sham-controlled trial testing intravitreal KSI-101 in patients with a central subfield thickness of at least 400 microns and best-corrected visual acuity (BCVA, a standardized eye-chart score) between 25 and 70 ETDRS letters. The primary endpoint is mean change in BCVA. New+1New data for Kodiak's KSI-101 from the APEX study reinforce its clinically meaningful vision gains and rapid retinal drying in macular edema secondary to inflammation (MESI)Sep 15, 2025A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAKNCT06990399
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
The precedent it must clear
The bar PEAK has to clear was set by Kodiak's own Phase 1b APEX study, a three-arm, open-label trial (no control group) that dosed 39 patients across three dose levels. In that cohort, 62% of patients on the 5 mg dose and 54% on the 10 mg dose gained at least 15 letters on the BCVA eye chart by week 12, and over 90% of patients achieved retinal dryness by week 8 after a single dose. Cleveland Clinic retina specialist Sumit Sharma said the drying effect was "on par with or even better than expected with the intraocular steroid implants such as Ozurdex but with none of the side effects". PEAK now has to reproduce that pattern in a larger, randomized population measured against a sham injection rather than against no comparator at all. NewNew data for Kodiak's KSI-101 from the APEX study reinforce its clinically meaningful vision gains and rapid retinal drying in macular edema secondary to inflammation (MESI)Sep 15, 2025
Timeline versus registry
PEAK's own registry record shows a primary completion date that moved from December 2026 to February 2026 in September 2025, then out to April 2027 in May 2026, alongside an enrollment target increase from 150 to 600 patients. Kodiak's public guidance quarter for the readout has not moved through any of those changes. The trial is expected to run 898 days from its July 2025 start to its current primary completion date, and it remains in Recruiting status as of the most recent registry update. NCT06990399+1A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAKNCT06990399New data for Kodiak's KSI-101 from the APEX study reinforce its clinically meaningful vision gains and rapid retinal drying in macular edema secondary to inflammation (MESI)Sep 15, 2025
Where it sits competitively
No other Phase 3 program in macular edema secondary to inflammation combines IL-6 and VEGF blockade; the only other trial in the indication is Kodiak's own PINNACLE study of the same drug. That leaves PEAK without a same-mechanism precedent inside its own disease population. Given the absence of an approved therapy in MESI, a Phase 3 result that reproduces the letter gains and drying rate seen in the Phase 1b cohort against a sham comparator, and that holds up across the larger 600-patient population, is the result that would establish KSI-101 as a viable treatment option. NCT06990399A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAKNCT06990399
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.